Sign up for free.
Pulmonx is an innovative medical technology company specializing in the development and marketing of minimally invasive solutions for the treatment of severe lung diseases[1][2]. With headquarters in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx positions itself as a global leader in interventional lung diagnostics, planning tools, and treatments for obstructive lung diseases[1].
The flagship product of Pulmonx is the Zephyr® Endobronchial Valve, a groundbreaking medical device for bronchoscopic lung volume reduction[1][2]. This innovative system allows patients with severe pulmonary emphysema to undergo non-surgical treatment without the risks of open surgery[1]. The Zephyr Valve received "breakthrough technology" status from the FDA (US Food and Drug Administration) in June 2018 and was approved[1][2]. The valve had already received CE marking in Europe in 2003[2].
In addition to the Zephyr Valve, Pulmonx offers additional technologies such as the StratX® Lung Analysis Platform and the Chartis System, which is used to predict treatment success[4]. The company has also expanded with the product AeriSeal through the acquisition of Aeris Therapeutics in 2014[4].
The Mission of Pulmonx is to be the world's leading and trusted partner in the assessment and treatment of severe lung diseases[2]. The company is committed to developing and marketing evidence-based solutions to improve patients' breathing and quality of life[2].
The corporate values form the foundation of the business:
Pulmonx is committed to building a strong scientific foundation for its technologies[1]. The company has published several significant clinical trials, including:
These research results have been considered by recognized institutions such as the FDA, the National Institute for Health and Care Excellence (NICE) in the UK and other authorities[1].
Pulmonx is a commercially active company with a strong international presence[3]. The products are commercially available in Europe, the USA, Australia, Asia, Latin America and many other countries worldwide[1]. The company currently employs approximately 291 people[3] and is experiencing continuous growth in its medical product sales, which have increased from $32.73 million in 2020 to $83.79 million in 2024[3].
In Germany, Pulmonx is represented by a branch in Munich, which functions as a regional competence center[2].
Pulmonx is led by an experienced management team consisting of industry veterans with extensive expertise in medical technology, clinical affairs and business development[8]. The management team brings decades of experience, particularly in the development and commercialization of revolutionary procedures for the treatment of lung diseases[8].
Pulmonx stands for innovation, patient-centeredness and scientific excellence in pulmonology and is committed to helping patients worldwide breathe easier and achieve a better quality of life[9].
